Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00033592 · ClinicalTrials.gov registry record · Phase 3
Comparison of Nicotine Inhaler and/or Bupropion in Helping People to Stop Smoking and Prevent the Recurrence of Smoking
A Phase 3 study of Lung Cancer, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,708
- Enrollment target
- 20
- Study locations
NCT00033592: Completed Phase 3 study of Lung Cancer, sponsored by Alliance for Clinical Trials in Oncology.
NCT00033592 is a Phase 3 study of Lung Cancer that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 1,708 participants, above the 932-participant average among 409 other Lung Cancer trials with a reported enrollment target (83% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00033592, a Phase 3 study of Lung Cancer, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,708 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Use of a nicotine inhaler and/or bupropion may be effective in helping people stop smoking and prevent them from starting smoking again. It is not yet known whether a nicotine inhaler or bupropion are more effective alone or combined for stopping smoking. PURPOSE: Randomized phase III trial to compare the effectiveness of the nicotine inhaler or bupropion alone to that of the nicotine inhaler combined with bupropion in helping people to stop smoking and prevent starting smoking again.
Conditions Studied
Interventions
- OTHER placebo
- DRUG bupropion hydrochloride
- DRUG nicotine
Study Locations (20)
Minnesota
- CCOP - Duluth - Duluth
- Mayo Clinic Cancer Center - Rochester
- CentraCare Clinic - Saint Cloud
- CCOP - Metro-Minnesota - Saint Louis Park
Iowa
- CCOP - Cedar Rapids Oncology Project - Cedar Rapids
- CCOP - Iowa Oncology Research Association - Des Moines
- Siouxland Hematology-Oncology - Sioux City
North Dakota
- Medcenter One Health System - Bismarck
- CCOP - Merit Care Hospital - Fargo
- Altru Health Systems - Grand Forks
Illinois
- CCOP - Illinois Oncology Research Association - Peoria
- CCOP - Carle Cancer Center - Urbana
Kansas
- CCOP - Wichita - Wichita
- Cancer Center of Kansas - Wichita - Wichita
Arizona
- CCOP - Scottsdale Oncology Program - Scottsdale
District of Columbia
- MBCCOP-Howard University Cancer Center - Washington D.C.
Louisiana
- CCOP - Ochsner - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,708 participants |
| Start Date | 2002-02 |
| Est. Completion | 2006-07 |
| Phase | Phase 3 |
What the finished NCT00033592 record still lists
NCT00033592 is an interventional study that assigns participants to a tested intervention. Its 1,708 participants enrollment target places it among the larger protocols in the corpus, above the 932-participant average among 409 other Lung Cancer trials with a reported enrollment target (83% higher).
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.
NCT00033592 names 20 study sites across 11 states, led by Minnesota, Iowa, North Dakota.
Frequently Asked Questions
What is clinical trial NCT00033592 about?
NCT00033592 is a clinical study titled "Comparison of Nicotine Inhaler and/or Bupropion in Helping People to Stop Smoking and Prevent the Recurrence of Smoking". RATIONALE: Use of a nicotine inhaler and/or bupropion may be effective in helping people stop smoking and prevent them from starting smoking again. It is not yet known whether a nicotine inhaler or bupropion are more effective alone or combined for stopping smoking. PURPOSE: Randomized phase III tr...
What is the current status of trial NCT00033592?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,708 participants. The study started on 2002-02. Estimated completion is 2006-07.
What conditions does trial NCT00033592 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT00033592?
The interventions under investigation include: placebo (OTHER), bupropion hydrochloride (DRUG), nicotine (DRUG).
Who is sponsoring clinical trial NCT00033592?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00033592 being conducted?
This trial has 20 study locations across Arizona, District of Columbia, Illinois, Iowa, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00033592's enrollment target sits among peer trials
1,708 34th of 409 higher than 376 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
ACTIVE NOT RECRUITING · Phase 3
-
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
COMPLETED · Phase 3
-
Gemcitabine and Carboplatin Followed By Docetaxel in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05303636 · 1,710 participants · Phase 4
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women
- NCT07304531 · 1,705 participants
First To Know Pregnancy Test - Clinical Evaluation Protocol
- NCT04291612 · 1,715 participants
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
- NCT04321200 · 1,700 participants
PANDA Gym: Automated Assessment of Neurodevelopment in Infants at Risk for Motor Disability
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia